Latest Breaking News On - Jian ni - Page 1 : comparemela.com
China s Unlikely Cameo in the Georgia Governor s Race
globalatlanta.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalatlanta.com Daily Mail and Mail on Sunday newspapers.
Gwinnett Chamber Signs Agreement With Chinese Business Association of Atlanta
globalatlanta.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalatlanta.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China .
Apollomics, Inc.February 12, 2021 GMT
FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, Feb. 12, 2021 (GLOBE NEWSWIRE) Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement for the development and commercialization of TYG100 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China, and South Africa.
TYG100 is an antigen-specific, active checkpoint control immunotherapy (ACCI) recombinant vaccine comprising the amino-terminal sequence of G17, a gastrointestinal peptide hormone, and utilizes the S-TIR™ technology platform. This technology induces a novel mechanism of action that is able to unmask tumors. TYG100 was developed by T
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
TYG100 utilizes proprietary S-TIR(TM) technology platform enabling specific B cell and T cell responses against tumor antigens
Foster City, CA & Hangzhou, CH, Feb 12, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement for the development and commercialization of TYG100 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China, and South Africa.
TYG100 is an antigen-specific, active checkpoint control immunotherapy (ACCI) recombinant vaccine comprising the amino-terminal sequence of G17, a gastrointestinal peptide hormone, and utilizes the S-TIR(TM) technology platform. This technology induces a novel mechanism of action that is able to unmask tumors. TYG100 was developed by TYG oncology